Navigation Links
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
Date:12/4/2010

Poster III  
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-383

  • Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) in Primary Thrombocythemia

    • Presenter: Gillian Stephens, Ph.D., Portola Pharmaceuticals
    • Poster Session: Pathophysiology of Thrombosis: Poster II
    • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
    • Location: Hall A3/A4 (Orange County Convention Center)
    • Poster Board III-997

    About Portola Pharmaceuticals, Inc.

    Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible direct-acting i.v. and oral P2Y12 ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care antiplatelet and anticoagulant markets.

    Portola's proprietary pipeline programs are focused on the discovery and development of PRT064445, a novel recombinant protein anticoagulant antidote, known as the Factor Xa inhibitor antidote, to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in
    '/>"/>

    SOURCE Portola Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
    2. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
    3. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
    4. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
    5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
    6. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
    7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
    8. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
    9. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
    10. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
    11. Onyx Pharmaceuticals Announces December 2010 Investor Events
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... 19, 2014  Diplomat, the nation,s largest independent specialty ... to the Board of Directors on September 15, ... also serve as chair of the Audit Committee. ... accounting, financial, compliance and operating experience in the health ... as chief financial officer, chief operating officer and secretary ...
    (Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
    (Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
    Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
    ... a quadriplegic triathlete, has been named spokesperson for National ... with disabilities to live active, mobile lifestyles. The goal ... well as the many other transportation solutions that can ... those with disabilities. Savicki is a proud partner along ...
    ... In the Middle East and North Africa ... MENA region are among the top 10 globally with the ... Bahrain, Egypt, Kuwait, Oman and Saudi Arabia. The region spends ... its total health care expenditure and expenditure averages as high ...
    Cached Medicine Technology:69-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 269-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 3Meeting of the Region's Top Diabetes Experts in Dubai this March 2
    (Date:9/20/2014)... "As a nurse, patients always ask me ... inventor from Tamaqua, Pa. "The reason that they cannot tell ... their chairs. My invention enables them to check oxygen levels ... to make it easier to monitor the contents of an ... the tank is low. It allows changeovers to be performed ...
    (Date:9/20/2014)... 2014 Earlier this week, Home Depot revealed ... had their credit card information pilfered by hackers, surpassing the ... of headline articles like this one published by ... opening numbers. , “Most people tend to focus on ... a way to score a game,” says Joe Caruso, founder ...
    (Date:9/20/2014)... (PRWEB) September 20, 2014 Final Cut ... announced the release of the Information theme for FCPX filmmakers. ... use to describe the Information theme,” says Christina Austin, CEO ... to look so professional.” , Information features easy to use ... parameters of the environment. Change the background color, color of ...
    (Date:9/20/2014)... “Motherhood is a wonderful gift and a huge responsibility,” ... article , “We know that you want to care for ... want to do as well.” , The article explains to ... their Family Physicians who practice obstetrics while pregnant, during delivery, ... To learn more about Community Health Center of Snohomish County ...
    (Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving forward in ... took place to discuss the next steps in ... mass tort program. Attorneys for the plaintiffs and defendants ... Complex Litigation Center in Philadelphia’s City Hall where the ... lawsuits filed against Johnson & Johnson and its subsidiary, ...
    Breaking Medicine News(10 mins):Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4
    ... researchers at Duke University Medical Center and the Universit catholique ... important energy source for tumor cells. In further experiments, they ... tumor cells by preventing them from delivering lactic acid. ... that low-oxygen, or hypoxic, cells cause resistance to radiation therapy," ...
    ... Therapeutics Inc., a leader,in the development of predictive ... funding to expand the development and commercialization of,ChemoFx(R). ... physicians select the,most effective chemotherapeutic regimen for cancer ... the round and was joined by existing,investors Adams ...
    ... ALEXANDRIA, Va., Nov. 20 Yesterday, America,s Health Insurance ... decided to support an "individual mandate," which requires everyone ... with "guaranteed issue," meaning that everyone must be accepted ... , But the Council for Affordable Health ...
    ... KANSAS CITY, Mo., Nov. 20 An investor group in ... developer and manufacturer of,diagnostic products whose shares are traded in ... Clint Severson has joined the company,s,board of directors. , ... Reidy stated, "We are delighted that Clint has,agreed to serve ...
    ... relatives at risk for hospital visits of their own , , ... care for a loved one with Alzheimer,s results in 25 ... or hospital visit every six months, says an Indiana University ... of an Alzheimer,s patient is difficult, but the Indiana University ...
    ... infection that can cause meningitis, pneumonia in young children, ... officials said Thursday that a shortage of vaccine is ... most important causes of bacterial illness in young children. ... increase in cases, the stepped-up surveillance was prompted by ...
    Cached Medicine News:Health News:Lactic acid found to fuel tumors 2Health News:Precision Therapeutics Secures $43 Million in Venture Capital Funding 2Health News:Precision Therapeutics Secures $43 Million in Venture Capital Funding 3Health News:CAHI Stands by Its Principles for Health Insurance Reform 2Health News:Investor Group Commends Clint Severson for Joining Trinity Biotech's Board of Directors 2Health News:When the Caregiver Becomes the Patient 2Health News:CDC Monitors Shortage of Hib Vaccine 2Health News:CDC Monitors Shortage of Hib Vaccine 3
    Shandon Plastic Slide Boxes...
    Shandon Cardboard Slide Folders...
    ... The new Propaq LT is the ... environment--combining the basic parameters of continuous vital ... new design, making it perfect for just ... place. , Light enough to clip on ...
    Exxcel Soft ePTFE vascular graft, designed for exceptional kink resistance and crush resistance, maintains a Soft touch for easier handling during peripheral vascular bypass procedures and vascular a...
    Medicine Products: